Companies · Pharmaceuticals

JDP Therapeutics, Inc.

PHILADELPHIA · Pharmaceuticals

Diligence memoA one-page analyst read on JDP Therapeutics, Inc. — recommendation, valuation, rhythm, risks.
$2.8M
Total raised · real
5
Rounds
10.0×
Latest step-up
Top 69%
Sector rank · raised
Seed
Latest stage · inferred · Mon Jun 20 2016 00:00:00 GMT+0000 (Coordinated Universal Time)

JDP Therapeutics, Inc. looks fair against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 1.26× the median modeled value of Seed Pharmaceuticals companies in 2016–2018 (71 peers) — value vs value, same stage and era.
  • Within the normal band (126% of peer median) for its niche.
Dormant
  • Last raise 10.0 yr ago; this sector typically re-raises about every 13 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Pharmaceuticals

JDP Therapeutics, Inc. is one of 1613 Pharmaceuticals companies tracked from PHILADELPHIA. By capital raised it ranks in the long tail (ahead of 32% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$25M$50M$75M$100MPre-Seed · 2010-09-20 Raised $300K (real) Modeled valuation $14M (est)$300K$14MPre-Seed2010Pre-Seed · 2010-09-20 Raised $125K (real) Modeled valuation $5.9M (est)$125K$5.9MPre-Seed2010Pre-Seed · 2011-04-25 Raised $175K (real) Modeled valuation $8.3M (est)$175K$8.3MPre-Seed2011Pre-Seed · 2013-02-15 Raised $200K (real) Modeled valuation $9.5M (est)$200K$9.5MPre-Seed2013Seed · 2016-06-20 Raised $2.0M (real) Modeled valuation $76M (est)$2.0M$76MSeed2016+$125K+$175K+$200K+$2.0MCumulative $2.8M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$300K · 2010
Pre-Seed extension$125K · 2010
Pre-Seed extension$175K · 2011
Pre-Seed extension$200K · 2013
Seed$2.0M · 2016

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$76.1M
Base estimate est.
$1.5M
Conservative case
$597.0M
Upside case
$10.0M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Seeda $1.0M–$4.0M round). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $14.2M · 2010-09-202010Pre-Seed · modeled $5.9M · 2010-09-20Pre-Seed · modeled $8.3M · 2011-04-25Pre-Seed · modeled $9.5M · 2013-02-15Seed · modeled $76.1M · 2016-06-202016
Model inputs · modeled:benchmark-stage-stepup-v1
20%
Dilution assumption
Implied ownership sold in the financing.
34%
Survival probability
15% low · 52% high
1.68×/yr
Annual markup
2.20×/yr upside case
6.0 yr
Elapsed time used
10.0 yr actual, capped for stale marks
pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
17 mo
Avg between rounds
$487K/yr
Capital velocity
15.8 yr
On record since
2010
First round
5
Rounds on file
How it compares to the market

Benchmarked against 1613 companies in Pharmaceuticals. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.3× of median
This company$2.8M
Sector median$8.1M
Latest round — vs other Seed rounds in sector (real $, this stage) 1.2× above median
This company$2.0M
Sector median$1.7M
Modeled value — vs sector median (estimate, all stages) 1.0× above median
This company$76.1M
Sector median$76.1M

Raised more than 32% of sector peers (real $). Modeled value above 50% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #32 of 71.

This companyCohort peer
$10.0M$100.0M$1.0B$1.0M$10.0MCapital raised (log)Chase Therapeutics Corp · Seed Raised $5.3M · modeled $152.2M (est)Acura Pharmaceuticals, Inc · Seed Raised $4.0M · modeled $152.2M (est)Paragon Biosciences Skyline Capital, LLC · Seed Raised $4.0M · modeled $150.9M (est)Phoenix PharmaLabs Inc · Seed Raised $3.5M · modeled $133.1M (est)Saghmos Therapeutics, Inc. · Seed Raised $3.5M · modeled $133.1M (est)Immucell Corp /De/ · Seed Raised $3.5M · modeled $131.8M (est)Madrigal Pharmaceuticals, Inc. · Seed Raised $3.4M · modeled $128.4M (est)Hydropothecary Corp · Seed Raised $3.3M · modeled $124.6M (est)SapVax, LLC · Seed Raised $3.3M · modeled $123.6M (est)VersaPeutics, Inc. · Seed Raised $3.8M · modeled $121.7M (est)Westwood Life Sciences, Llc · Seed Raised $3.1M · modeled $116.3M (est)Har-Kcy, Llc · Seed Raised $3.0M · modeled $114.3M (est)JDP Therapeutics, Inc. (this company) Raised $2.8M · modeled $76.1M (est)JDP Therapeutics, Inc.
CompanyStageRaised · realValue · estvs peer med.
Chase Therapeutics CorpSeed$5.3M$152.2M2.52×
Acura Pharmaceuticals, IncSeed$4.0M$152.2M2.52×
Paragon Biosciences Skyline Capital, LLCSeed$4.0M$150.9M2.50×
Phoenix PharmaLabs IncSeed$3.5M$133.1M2.21×
Saghmos Therapeutics, Inc.Seed$3.5M$133.1M2.21×
Immucell Corp /De/Seed$3.5M$131.8M2.19×
Madrigal Pharmaceuticals, Inc.Seed$3.4M$128.4M2.13×
Hydropothecary CorpSeed$3.3M$124.6M2.07×
SapVax, LLCSeed$3.3M$123.6M2.05×
VersaPeutics, Inc.Seed$3.8M$121.7M2.02×
Westwood Life Sciences, LlcSeed$3.1M$116.3M1.93×
Har-Kcy, LlcSeed$3.0M$114.3M1.90×
JDP Therapeutics, Inc. this companySeed$2.8M$76.1M1.26×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$300K2010-09-20$1.7M$14.2M90%
Pre-Seed$125K2010-09-20$694K$5.9M90%
Pre-Seed$175K2011-04-25$972K$8.3M90%
Pre-Seed$200K2013-02-15$1.1M$9.5M90%
Seed$2.0M2016-06-20$10.0M$76.1M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$300K2010-09-20
    • First recorded raise — entered as Pre-Seed.
  2. Pre-Seed$125K2010-09-20
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 2.4× smaller than the prior — bridge or down round.
  3. Pre-Seed$175K2011-04-25
    • Came back fast: 7 mo vs the ~13 mo sector norm.
    • Round 1.4× larger than the prior — scaling up.
  4. Pre-Seed$200K2013-02-15
    • Raised again after 22 mo — slower than the ~13 mo sector norm.
    • Round roughly the size of the prior one.
  5. Seed$2.0M2016-06-20
    • Raised again after 40 mo — slower than the ~13 mo sector norm.
    • Round 10.0× larger than the prior — scaling up.
Intelligence
2017 ~Q4
Modeled next raise · ~17mo cadence
$6.0M
Modeled next size est.range $3.9M$9.6M
10.0×
Last step-up
$487K/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Christopher M. Cashman5 other2010-09
John M. Morrash1 other2013-02
Joshua M. Tarnoff1 other2010-09
Jie Du2010-09
Jonathan H. Black2010-09
Registry & provenance

JDP Therapeutics, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1488520
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Amplicore Inc.PharmaceuticalsSeed$2.8M$107.1Msame sector · same stage
Melior Discovery, IncPharmaceuticalsSeed$2.8M$66.3Msame sector · same stage
iTherX Pharmaceuticals, Inc.PharmaceuticalsSeed$2.8M$105.8Msame sector · same stage
Harbor BioSciences, Inc.PharmaceuticalsSeed$2.8M$107.5Msame sector · same stage
Western Oncolytics LTD.PharmaceuticalsSeed$2.8M$95.1Msame sector · same stage
Cane Ip Leading Holdings, LlcPharmaceuticalsSeed$2.8M$104.8Msame sector · same stage
Lotus Tissue Repair, Inc.PharmaceuticalsSeed$2.8M$104.6Msame sector · same stage
Cardax Pharma, Inc.PharmaceuticalsSeed$2.9M$79.0Msame sector · same stage
Frequently asked
How much funding has JDP Therapeutics, Inc. raised?
JDP Therapeutics, Inc. has raised approximately $2.8M in disclosed capital across 5 recorded financing rounds, aggregated from public filings.
What is JDP Therapeutics, Inc.'s estimated valuation?
Provath's modeled valuation for JDP Therapeutics, Inc. is approximately $76.1M (modeled range $1.5M–$597.0M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is JDP Therapeutics, Inc. at?
JDP Therapeutics, Inc.'s latest modeled financing stage is Seed. Its most recent recorded round closed around Mon Jun 20.
What does JDP Therapeutics, Inc. do and where is it based?
JDP Therapeutics, Inc. operates in the Pharmaceuticals sector, based in PHILADELPHIA.
Explore related

See where JDP Therapeutics, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at JDP Therapeutics, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.